Zealand Pharma's deficit grows in quarter with product divestment
![Photo: Zealand Pharma / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13878550.ece/ALTERNATES/schema-16_9/doc7kclnpsrsgza4f9n1pk.jpg)
Zealand Pharma has been busy during the year’s second quarter, where the biotech firm completed a directed share issuance, received data from the substance dapiglutide against obesity and sold off insulin pump V-Go.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Zealand Pharma issues almost USD 40m in shares
For subscribers
Zealand Pharma to delist in US
For subscribers